Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Ontario, Canada.
Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Ontario, Canada.
Transplant Cell Ther. 2023 Feb;29(2):131.e1-131.e6. doi: 10.1016/j.jtct.2022.10.028. Epub 2022 Nov 4.
Increasing use of hematopoietic stem cell transplantation (HCT) and improvements in recipient outcomes have led to a steady increase in the number of allogeneic HCT survivors. In addition to complications specific to the transplantation process, HCT recipients are at increased risk of developing cardiovascular disease (CVD) and subsequent neoplasm (SN). Strict surveillance of risk factors for CVD and cancer in the general population is recommended as an essential component of long-term follow-up (LTFU) care of HCT survivors, but implementation of this has been suboptimal. Various models for improving the provision of survivorship care have been proposed, including a hybrid/combined care approach wherein the HCT provider manages transplantation-specific complications and the primary care physician (PCP) provides general medical care, including surveillance and aggressive management of CVD risk factors and screening for SN. This model also offers a practical approach to LTFU care for HCT survivors who live at a distance from the HCT center, which is a reality for many recipients of HCT at The Ottawa Hospital (TOH). As the success of such a hybrid approach to survivorship care depends on the engagement of HCT recipients with their PCP and compliance with recommended general population surveillance, the aim of the present study was to assess the rates of PCP attendance and adherence to recommended preventive medicine interventions in the years immediately before and after HCT. We hypothesized that rates would be suboptimal and planned to use these results as a baseline for an educational initiative aimed at increasing awareness of HCT recipients and their PCPs about embracing preventive survivorship care. This was a single-center cohort study of allogeneic HCT recipients who underwent transplantation at TOH with linkage to population-based health administrative data. Published clinical practice guidelines were used to define recommended screening for CVD risk factors and cancer. The rates of annual PCP visits and utilization of recommended preventive care interventions in the 5 years before and after HCT were calculated for all eligible patients. Between 2014 and 2020, 409 patients with provincial health care coverage underwent allogeneic HCT at TOH. The median patient age was 51 years (range, 15 to 73 years), with a male predominance (60.9%). Approximately one-quarter of recipients did not attend a PCP visit in the 5 years before and after transplantation, and this proportion increased to one- third in the fifth year post-HCT. Among those recipients who were eligible, only 20% to 25% underwent recommended screening for dyslipidemia and diabetes. Cancer screening rates were also low, at 16% to 18% for cervical cancer, 18% to 22% for colon cancer, and 30% to 31% for breast cancer. These results highlight the need to increase awareness of HCT recipients and their PCPs about the risk of developing CVD and SN post-transplantation and to emphasize the potential to mitigate this risk by adhering to recommendations for surveillance to enable prompt intervention. Patient education should incorporate this information and empower HCT survivors to actively engage in their follow-up care and optimize their long-term outcomes.
越来越多的患者接受了造血干细胞移植(HCT),并且受者的预后得到了改善,这导致异基因 HCT 幸存者的数量稳步增加。除了与移植过程相关的特定并发症外,HCT 受者罹患心血管疾病(CVD)和随后的肿瘤(SN)的风险也会增加。建议对 CVD 和癌症的危险因素进行严格监测,作为 HCT 幸存者长期随访(LTFU)护理的重要组成部分,但目前这方面的实施情况并不理想。已经提出了各种改善生存护理提供的模型,包括混合/联合护理方法,其中 HCT 提供者管理移植特异性并发症,而初级保健医生(PCP)提供一般医疗护理,包括 CVD 危险因素的监测和积极管理以及 SN 的筛查。对于居住在 HCT 中心以外的 HCT 幸存者,这种 LTFU 护理模式为其提供了一种实用的方法,这也是安大略省渥太华医院(TOH)接受 HCT 的许多受者的现实情况。由于这种混合生存护理方法的成功取决于 HCT 受者与 PCP 的参与以及对推荐的一般人群监测的依从性,因此本研究的目的是评估在 HCT 前后的几年中 PCP 就诊和遵守推荐的预防医学干预措施的比率。我们假设该比率不理想,并计划将这些结果用作旨在提高 HCT 受者及其 PCP 对接受预防生存护理意识的教育计划的基线。这是一项对在 TOH 接受 HCT 的异基因 HCT 受者进行的单中心队列研究,并与基于人群的健康管理数据进行了关联。使用已发表的临床实践指南来定义 CVD 危险因素和癌症的推荐筛查。计算了所有符合条件的患者在 HCT 前后 5 年内每年 PCP 就诊和使用推荐的预防保健干预措施的比率。在 2014 年至 2020 年间,有 409 名有省级医疗保险的患者在 TOH 接受了异基因 HCT。患者的中位年龄为 51 岁(范围为 15 至 73 岁),男性居多(60.9%)。大约四分之一的受者在移植前后的 5 年内没有就诊过 PCP,而在移植后的第 5 年,这一比例增加到了三分之一。在符合条件的受者中,只有 20%至 25%接受了推荐的血脂异常和糖尿病筛查。癌症筛查率也较低,宫颈癌为 16%至 18%,结肠癌为 18%至 22%,乳腺癌为 30%至 31%。这些结果强调了需要提高 HCT 受者及其 PCP 对移植后发生 CVD 和 SN 的风险的认识,并强调通过坚持建议的监测来降低这种风险的潜力,以便及时进行干预。患者教育应包含这些信息,并使 HCT 幸存者能够积极参与其随访护理,从而优化其长期结局。